Induction of NAD(P)H quinone: Oxidoreductasel inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 6, 2003, Pages 566-572

  Begleiter, Asher ^a,b   Sivananthan, Kosala ^a,b   Curphey, Thomas J ^c   Bird, Ranjana P ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c DARTMOUTH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZOQUINONE; AZOXYMETHANE; DICOUMAROL; GLUCURONOSYLTRANSFERASE; GLUTAMIC ACID DIMETHYL ESTER; OLTIPRAZ; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; CRYPT CELL; ENZYME ACTIVITY; ENZYME INDUCTION; GROWTH INHIBITION; INTESTINE CRYPT; LIVER PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; COLON; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; FUMARATES; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INTESTINAL MUCOSA; LIVER; MALE; METABOLIC DETOXICATION, DRUG; NAD(P)H DEHYDROGENASE (QUINONE); NADP; PYRAZINES; RADIATION-SENSITIZING AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0038796599     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Cancer Facts and Figures 2003. American Cancer Society, Inc., 2003.
2. Kim, Y., and Mason, J. B. Nutrition chemoprevention of gastrointestinal cancers: a critical review. Nutr. Rev., 54: 259-279, 1996.
3. Doll, R., and Peto, R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. (Bethesda), 66:1191-1308, 1981.
4. Wargovich, M. J., Chen, C-D., Jimenez, A., Steele, V. E., Velasco, M., Stephens, C., Price, R., Gray, K., and Kelloff, G. J. Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol. Biomark. Prev., 5: 355-360, 1996.
5. Talalay, P., and Zhang, Y. Chemoprotection against cancer by isothiocyanates and glucosinolates. Biochem. Soc. Trans., 24: 806-810, 1996.
6. Hecht, S. S. Chemoprevention by isothiocyanates. J. Cell. Biochem., 22 (Suppl.):195-209, 1995.
7. Kensler, T. W., Groopman, J. D., and Roebuck, B. D. Chemoprotection by oltipraz and other dithiolethiones. In: L. Wattenberg, M. Lipkin, C. Boone, and G. Kelloff (eds.), Cancer Chemoprevention. pp. 205-225. Boca Raton, FL: CRC Press, 1992.
8. Morse, M. A., and Stoner, G. D. Cancer chemoprevention. Carcinogenesis (Lond.), 14:1737-1746, 1993.
9. Sugie, S., Okamoto, K., Okumura, A., Tanaka, T., and Mori, H. Inhibitory effects of benzyl thiocyanate and benzyl isothiocyanate on methylazoxymethanol acetate-induced intestinal carcinogenesis in rats. Carcinogenesis (Lond.), 15:1555-1560, 1994.
10. Smith, T., Musk, S. R. R., and Johnson, I. T. Allyl isothiocyanate selectively kills undifferentiated HT29 cells in vitro and suppresses aberrant crypt foci in the colonic mucosa of rats. Biochem. Soc. Trans., 24: 381S, 1996.
11. Archer, S. The chemotherapy of schistosomiasis. Ann. Rev. Pharmacol. Toxicol., 25: 485-508, 1985.
12. Clapper, M. L. Chemopreventive activity of oltipraz. Pharmacol. Ther., 78:17-27, 1998.
13. Zhang, B-C., Zhu, Y-R., Wang, J-B., Wu, Y., Zhang, Q-N., Qian, G-S., Kuang, S-Y., Li, Y-F., Fang, X., Yu, L-Y., De Flora, S., Jacobson, L. P., Zarba, A., Egner, P. A., He, X., Wang, J-S., Chen, B., Enger, C. L., Davidson, N. E., Gordon, G. B., Gorman, M. B., Prochaska, H. J., Groopman, J. D., Munoz, A., Helzlsouer, K. J., and Kensler, T. W. Oltipraz chemoprevention trial in Qidong, Jiangsu Province. People's Republic of China. J. Cell. Biochem., 28/29 (Suppl.):166-173, 1997.
14. Wang, J. S., Shen, X., He, X., Zhu, Y. R., Zhang, B. C., Wang, J. B., Qian, G. S., Kuang, S. Y., Zarba, A., Egner, P. A., Jacobson, L. P., Munoz, A., Helzlsouer, K. J., Groopman, J. D., and Kensler, T. W. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong. People's Republic of China. J. Natl. Cancer Inst. (Bethesda), 91: 347-354, 1999.
15. Camoirano, A., Bagnasco, M., Bennicelli, C., Cartiglia, C., Wang, J. B., Zhang, B. C., Zhu, Y. R., Qian, G. S., Egner, P. A., Jacobson, L. P., Kensler, T. W., and De-Flora, S. Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits. Cancer Epidemiol. Biomark. Prev., 10: 775-783, 2001.
16. Rao, C. V., Rivenson, A., Katiwalla, M., Kelloff, G. J., and Reddy, B. S. Chemopreventive effect of Oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res., 53: 2502-2506, 1993.
17. Ross, D., Siegel, D., Beall, H., Prakash, A. S., Mulcahy, R. T., and Gibson, N. W. DT-diaphorase in activation and detoxification of quinones. Cancer Metastasis Rev., 12: 83-101, 1993.
18. Riley, R. J., and Workman, P. DT-diaphorase and cancer chemotherapy. Biochem. Pharmacol., 43:1657-1669, 1992.
19. Ernster, L. DT-diaphorase: a historical review. Chemica Scripta, 27A:1-13, 1987.
20. Begleiter, A., Robotham, E., Lacey, G., and Leith, M. K. Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett., 45:173-176, 1989.
21. Begleiter, A., Leith, M. K., Curphey, T. J., and Doherty, G. P. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy. Oncol. Res., 9: 371-382, 1997.
22. Asher, G., Lotem, J., Cohen, B., Sachs, L., and Shaul, Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. USA, 98:1188-1193, 2001.
23. Long, D. J., II, Gaikwad, A., Multani, A., Pathak, S., Montgomery, C. A., Gonzalez, F. J., and Jaiswal, A. K. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res., 62: 3030-3036, 2002.
24. Jaiswal, A. K. Human NAD(P)H:quinone oxidoreductase (NQO-1) gene structure and induction by dioxin. Biochemistry, 30:10647-10653, 1991.
25. Jaiswal, A. K., Burnett, P., Adesnik, M., and McBride, O. W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry, 29:1899-1906, 1990.
26. Winski, S. L., Koutalos, Y., Bentley, D. L., Siegel, D., and Ross, D. Presence of NAD(P)H: quinone oxidoreductase 1 (NQO1) in the nucleus of human cancer cells. Proc. Am. Assoc. Cancer Res., 43: 270, 2002.
27. Belinsky, M., and Jaiswal, A. K. NAD(P)H:quinone oxidoreductasel (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev., 12:103-117, 1993.
28. Traver, R. D., Siegel, D., Beall, H. D., Phillips, R. M., Gibson, N. W., Franklin, W. A., and Ross, D. Characterization of a polymorphism in NAD(P)H: Quinone oxidoreductase (DT-diaphorase). Br. J. Cancer, 75: 69-75, 1997.
29. Kelsey, K. T., Ross, D., Traver, R. D., Christiani, D. C., Zuo, Z. F., Spitz, M. R., Wang, M., Xu, X., Lee, B. K., Schwartz, B. S., and Wiencke, J. K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer, 76: 852-854, 1997.
30. Gaedigk, A., Tyndale, R. E., Jurima-Romet, M., Sellers, E. M., Grant, D. M., and Leeder, J. S. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics, 8: 305-313, 1998.
31. Misra, V., Klamut, H. J., and Rauth, A. M. Transfection of COS-1 cells with DT-diaphorase cDNA: role of a base change at position 609. Br. J. Cancer, 77:1236-1240, 1998.
32. Begleiter, A., Leith, M. K., Doherty, G. P., Digby, T. J., and Pan, S. Factors influencing the induction of DT-diaphorase activity by 1, 2-dithiole-3-thione in human tumour cell lines. Biochem. Pharmacol., 61: 955-964, 2001.
33. Bird, R. P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett., 93: 55-71, 1995.
34. Bird, R. P. Aberrant crypt foci system to study cancer preventive agents in the colon. In: M. Hanausek and Z. Walaszek (eds.), Methods in Molecular Medicine, Vol. 14: Tumor Marker Protocols, pp. 465-474. Totowa, NJ: Humana Press, Inc., 1998.
35. Magnuson, B. A., Carr, I., and Bird, R. P. Ability of aberrant crypt foci characteristics to predict colonic tumour incidence in rats fed cholic acid. Cancer Res., 53: 4499-4504, 1993.
36. Bird, R. P., Yao, K., Lasko, C. M., and Good, C. K. Inability of low- or high-fat diet to modulate late stages of colon carcinogenesis in Sprague Dawley rats. Cancer Res., 56: 2896-2899, 1996.
37. Hamilton, S. R. Experimental models of colorectal carcinogenesis. In: H. K. Seitz, U. A. Simanowski, and N. A. Wright (eds), From Pathogenesis to Prevention, pp. 202-212. New York: Springer-Verlag, 1989.
38. Gullino, P. M., Pettigrew, H. M., and Grantham, F. H. N-Nitrosomethylurea as mammary gland carcinogen in rats. J. Natl. Cancer Inst. (Bethesda), 54: 401-414, 1975.
39. Weisburger, J. H., and Fiala, E. S. Experimental colon carcinogenesis and their mode of action. In: H. Autrup and G. M. Williams (eds), Experimental Colon Carcinogenesis, p. 27, Boca Raton. FL: CRC Press, 1983.
40. Swann, F. F. The rate of breakdown of methyl methanesulphonate, dimethyl sulphate and N-methyl-N-nitrosourea in the rat. Biochem. J., 110: 49-52, 1968.
41. Curphey, T. J. A superior procedure for the conversion of 3-oxoesters to 3H-1, 2-dithiole-3-thiones. Tetrahedron Lett., 41: 9963-9966, 2000.
42. Doherty, G. P., Leith, M. K., Wang, X., Curphey, T. J., and Begleiter, A. Induction of DT-diaphorase by 1, 2-dithiole-3-thiones in human tumor and normal cells and effect on antitumor activity ofbioreductive agents. Br. J. Cancer, 77:1241-1252, 1998.
43. Habig, W. H., Pabst, M. J., and Jakoby, W. B. Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. J. Biol. Chem., 249: 7130-7139, 1974.
44. Chengelis, C. P. Age- and sex-related changes in epoxide hydrolase, UDP-glucuronosyl transferase, gluathione S-transferase, and PAPS sulfotransferase in Sprague-Dawley rats. Xenobiotica, 18:1225-1237, 1988.
45. Prestera, T., Zhang, Y., Spencer, S. R., Wilczak, C. A., and Talalay, P. The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul., 33: 281-296, 1993.
46. Shapiro, T. A., Fahey, J. W., Wade, K. L., Stephenson, K. K., and Talalay, P. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol. Biomark. Prev., 10: 501-508, 2001.
47. Egner, P. A., Kensler, T. W., Prestera, T., Talalay, P., Libby, A. H., Joyner, H. H., and Curphey, T. J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis (Lond.), 15:177-181, 1994.
48. Spencer, S. R., Wilczak, C. A., and Talalay, P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res., 50: 7871-7875, 1990.
49. Christensen, F. Studies on the fate of intravenous dicoumarol in the rat. Acta Pharmacol. Toxicol., 21: 307-312, 1964.